BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 20143319)

  • 1. Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer.
    Urayama S; Zou W; Brooks K; Tolstikov V
    Rapid Commun Mass Spectrom; 2010 Mar; 24(5):613-20. PubMed ID: 20143319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Untargeted LC-HRMS-Based Metabolomics for Searching New Biomarkers of Pancreatic Ductal Adenocarcinoma: A Pilot Study.
    Ríos Peces S; Díaz Navarro C; Márquez López C; Caba O; Jiménez-Luna C; Melguizo C; Prados JC; Genilloud O; Vicente Pérez F; Pérez Del Palacio J
    SLAS Discov; 2017 Apr; 22(4):348-359. PubMed ID: 27655283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum metabolomics differentiating pancreatic cancer from new-onset diabetes.
    He X; Zhong J; Wang S; Zhou Y; Wang L; Zhang Y; Yuan Y
    Oncotarget; 2017 Apr; 8(17):29116-29124. PubMed ID: 28418859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic system alterations in pancreatic cancer patient serum: potential for early detection.
    Ritchie SA; Akita H; Takemasa I; Eguchi H; Pastural E; Nagano H; Monden M; Doki Y; Mori M; Jin W; Sajobi TT; Jayasinghe D; Chitou B; Yamazaki Y; White T; Goodenowe DB
    BMC Cancer; 2013 Sep; 13():416. PubMed ID: 24024929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct serum metabolomics profiles associated with malignant progression in the KrasG12D mouse model of pancreatic ductal adenocarcinoma.
    LaConti JJ; Laiakis EC; Mays AD; Peran I; Kim SE; Shay JW; Riegel AT; Fornace AJ; Wellstein A
    BMC Genomics; 2015; 16 Suppl 1(Suppl 1):S1. PubMed ID: 25923219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolomics identified new biomarkers for the precise diagnosis of pancreatic cancer and associated tissue metastasis.
    Luo X; Liu J; Wang H; Lu H
    Pharmacol Res; 2020 Jun; 156():104805. PubMed ID: 32278036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum Metabolomic Profiles for Human Pancreatic Cancer Discrimination.
    Itoi T; Sugimoto M; Umeda J; Sofuni A; Tsuchiya T; Tsuji S; Tanaka R; Tonozuka R; Honjo M; Moriyasu F; Kasuya K; Nagakawa Y; Abe Y; Takano K; Kawachi S; Shimazu M; Soga T; Tomita M; Sunamura M
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28375170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics.
    Yoneyama T; Ohtsuki S; Honda K; Kobayashi M; Iwasaki M; Uchida Y; Okusaka T; Nakamori S; Shimahara M; Ueno T; Tsuchida A; Sata N; Ioka T; Yasunami Y; Kosuge T; Kaneda T; Kato T; Yagihara K; Fujita S; Huang W; Yamada T; Tachikawa M; Terasaki T
    PLoS One; 2016; 11(8):e0161009. PubMed ID: 27579675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma Metabolome Profiling Identifies Metabolic Subtypes of Pancreatic Ductal Adenocarcinoma.
    Mahajan UM; Alnatsha A; Li Q; Oehrle B; Weiss FU; Sendler M; Distler M; Uhl W; Fahlbusch T; Goni E; Beyer G; Chromik A; Bahra M; Klein F; Pilarsky C; Grützmann R; Lerch MM; Lauber K; Christiansen N; Kamlage B; Regel I; Mayerle J
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabonomic alterations from pancreatic intraepithelial neoplasia to pancreatic ductal adenocarcinoma facilitate the identification of biomarkers in serum for early diagnosis of pancreatic cancer.
    Lin X; Zhan B; Wen S; Li Z; Huang H; Feng J
    Mol Biosyst; 2016 Aug; 12(9):2883-92. PubMed ID: 27400832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling.
    Hocker JR; Postier RG; Li M; Lerner MR; Lightfoot SA; Peyton MD; Deb SJ; Baker CM; Williams TL; Hanas RJ; Stowell DE; Lander TJ; Brackett DJ; Hanas JS
    Cancer Lett; 2015 Apr; 359(2):314-24. PubMed ID: 25637792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The metabolic time line of pancreatic cancer: Opportunities to improve early detection of adenocarcinoma.
    Moore HB; Culp-Hill R; Reisz JA; Lawson PJ; Sauaia A; Schulick RD; Del Chiaro M; Nydam TL; Moore EE; Hansen KC; D'Alessandro A
    Am J Surg; 2019 Dec; 218(6):1206-1212. PubMed ID: 31514959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-invasively predicting differentiation of pancreatic cancer through comparative serum metabonomic profiling.
    Wen S; Zhan B; Feng J; Hu W; Lin X; Bai J; Huang H
    BMC Cancer; 2017 Nov; 17(1):708. PubMed ID: 29096620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis of pancreatic cancer via
    Michálková L; Horník Š; Sýkora J; Habartová L; Setnička V
    Analyst; 2018 Dec; 143(24):5974-5978. PubMed ID: 30270368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum N-Glycome analysis reveals pancreatic cancer disease signatures.
    Vreeker GCM; Hanna-Sawires RG; Mohammed Y; Bladergroen MR; Nicolardi S; Dotz V; Nouta J; Bonsing BA; Mesker WE; van der Burgt YEM; Wuhrer M; Tollenaar RAEM
    Cancer Med; 2020 Nov; 9(22):8519-8529. PubMed ID: 32898301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein-metabolite panel for early-stage pancreatic cancer.
    Burki TK
    Lancet Oncol; 2018 Oct; 19(10):e512. PubMed ID: 30146244
    [No Abstract]   [Full Text] [Related]  

  • 17. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.
    Mayerle J; Kalthoff H; Reszka R; Kamlage B; Peter E; Schniewind B; González Maldonado S; Pilarsky C; Heidecke CD; Schatz P; Distler M; Scheiber JA; Mahajan UM; Weiss FU; Grützmann R; Lerch MM
    Gut; 2018 Jan; 67(1):128-137. PubMed ID: 28108468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolomic profile in pancreatic cancer patients: a consensus-based approach to identify highly discriminating metabolites.
    Di Gangi IM; Mazza T; Fontana A; Copetti M; Fusilli C; Ippolito A; Mattivi F; Latiano A; Andriulli A; Vrhovsek U; Pazienza V
    Oncotarget; 2016 Feb; 7(5):5815-29. PubMed ID: 26735340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of LC-MS-based metabolomics method in differentiating septic survivors from non-survivors.
    Liu Z; Yin P; Amathieu R; Savarin P; Xu G
    Anal Bioanal Chem; 2016 Nov; 408(27):7641-7649. PubMed ID: 27614981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Gastroenterological Cancer Diagnosis by Metabolomics-Discovery of Pancreatic Cancer Biomarker].
    Yoshida M; Nishiumi S; Azuma T
    Rinsho Byori; 2015 Apr; 63(4):450-6. PubMed ID: 26536778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.